We serve Chemical Name:fema 3227 CAS:5905-46-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:fema 3227
CAS.NO:5905-46-4
Synonyms:Acetic acid,phosphono-,1-propyl ester;Propylphosphonoacetat;1-Propyl phosphonoacetate;Acetic acid,phosphono-,propyl ester
Molecular Formula:C6H12S2
Molecular Weight:148.28900
HS Code:2930909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:185.9ºC at 760 mmHg
Density:0.994g/cm3
Index of Refraction:1.527
PSA:50.60000
Exact Mass:148.03800
LogP:3.31140
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Acetic acid,phosphono-,1-propyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Acetic acid,phosphono-,propyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acetic acid,phosphono-,propyl ester Use and application,Propylphosphonoacetat technical grade,usp/ep/jp grade.
Related News: The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development. fema 3227 manufacturer FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. fema 3227 supplier Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. fema 3227 vendor FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. fema 3227 factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
